Floatz logo

b7-h3 car t cells

Rhabdoid Tumor

St. Jude Children's Research HospitalCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

33 Active assets in the Rhabdoid Tumor cohort.

Asset / SponsorPhaseRating
Tazemetostat
Epizyme, Inc.
Phase 2BB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2B
Hycamtin
Pfizer
Phase 2B
Palbociclib
Pfizer
Phase 2B
Olaparib
National Cancer Institute (NCI)
Phase 2B

View all 44 →

Same molecule, other indications

b7-h3 car t cells is also rated in:

Pediatric Solid TumorDormant
CC
Indicative ·
43 / 100
View asset →
Wilms tumorDormant
CC
Indicative ·
43 / 100
View asset →
adrenal cortex carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →